Personalized drug dosing shows promise for kidney cancer patients
Disease control
Completed
This study looked at whether adjusting the dose of two standard kidney cancer drugs (sunitinib and pazopanib) based on the amount of drug in a patient's blood can improve treatment. The goal was to see if this personalized approach reduces side effects and helps keep the cancer f…
Phase: PHASE4 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC